Advancing gastroparesis care: Key findings from a 5 year study
This video highlights new 5-year data from the largest, independently conducted study on Enterra® Therapy. Listen as Dr. Awad shares how this study demonstrated statistically-significant reductions in symptoms and hospitalizations for those with chronic, refractory, gastroparesis.
Michael Awad, MD, PhD, MHPE, FACS
Department of Surgery
Washington University School of Medicine
St Louis, MO
IMPORTANT SAFETY INFORMATION
Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
HUMANITARIAN DEVICE
Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?